Collegium Pharmaceutical (NASDAQ:COLL) Stock Rating Lowered by Wall Street Zen

Collegium Pharmaceutical (NASDAQ:COLL) was downgraded by investment analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Saturday.

A number of other equities research analysts have also recently weighed in on COLL. Zacks Research upgraded Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Monday, June 29th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Collegium Pharmaceutical in a report on Monday, July 6th. Finally, Truist Financial upgraded Collegium Pharmaceutical to a “strong-buy” rating in a research report on Monday, June 15th. Two investment analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $57.50.

Collegium Pharmaceutical Price Performance

COLL stock opened at $35.20 on Friday. The company has a current ratio of 1.71, a quick ratio of 1.62 and a debt-to-equity ratio of 2.47. The company’s 50-day moving average price is $34.65 and its 200 day moving average price is $37.88. Collegium Pharmaceutical has a 52 week low of $29.19 and a 52 week high of $50.79. The company has a market cap of $1.14 billion, a P/E ratio of 17.25 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.52 by $0.24. Collegium Pharmaceutical had a net margin of 9.41% and a return on equity of 95.18%. The company had revenue of $193.52 million during the quarter, compared to analysts’ expectations of $184.47 million. During the same period last year, the company posted $1.49 earnings per share. The firm’s quarterly revenue was up 8.9% compared to the same quarter last year. On average, research analysts expect that Collegium Pharmaceutical will post 6.76 earnings per share for the current fiscal year.

Institutional Trading of Collegium Pharmaceutical

Several large investors have recently modified their holdings of COLL. Group One Trading LLC purchased a new position in shares of Collegium Pharmaceutical during the 4th quarter worth approximately $28,000. Caitong International Asset Management Co. Ltd raised its position in shares of Collegium Pharmaceutical by 205.3% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 427 shares during the last quarter. PNC Financial Services Group Inc. lifted its stake in Collegium Pharmaceutical by 42.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,408 shares of the specialty pharmaceutical company’s stock valued at $47,000 after buying an additional 418 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new stake in Collegium Pharmaceutical in the 4th quarter valued at approximately $61,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in Collegium Pharmaceutical by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 318 shares during the last quarter.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.